Breaking News

AMRI Wins UK Government Contract

September 30, 2013

Will supply product for Phase I trials

AMRI’s subsidiary, Albany Molecular Research (UK) Ltd., has been awarded a seven-year government contract for the development and manufacture of an active ingredient for clinical trials. The contract was awarded by the Defense Science and Technology Laboratory (Dstl), acting on behalf of the UK's Secretary of State for Defence, the Department of National Defence of Canada and Minister of Defence of the Kingdom of the Netherlands.
AMRI will provide development and scale-up of the investigational drug, and the manufacture and supply for Phase I trials. If the trials are successful, AMRI may also become the commercial manufacturer of the product for distribution to the government partners in the contract.
"We are excited for the opportunity to work on this important project for the UK government," said AMRI's president and chief executive officer, Thomas E. D'Ambra, Ph.D. "Government contracts and related collaborations outside of our typical outsourcing contracts with biotechnology and pharmaceutical companies are part of our strategy to diversify our revenue base while making our high-quality services available to all industries, sectors and organizations that can benefit from our strengths in discovery, development and manufacturing."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important